CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 47 enrolled
Drug / intervention
Pimavanserindrug
Likely dose
Pimavanserin 34 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03482882
NCT03482882Phase 2Completed
CompareCT.gov

An Open-label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults With Parkinson's Disease and Depression

ACADIA Pharmaceuticals Inc.·interventional·Posted Mar 29, 2018·Updated Aug 31, 2020

In Brief

A Phase 2 clinical trial evaluating Pimavanserin for Treatment of Depression in Adults With Parkinson's Disease (PD). Completed, enrolled 47 participants across 21 sites.

Detailed Summary

The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTreatment of Depression in Adults With Parkinson's Disease (PD)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartMar 9, 2018
Primary CompletionJul 9, 2019
Study CompletionJul 24, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.3 years ago

Interventions

Pimavanserindrug

Pimavanserin 34 mg total daily dose, tablets, once daily by mouth (provided as two 17 mg NUPLAZID® tablets)